Neuropsychopharmacologia Hungarica : a Magyar Pszichofarmakologiai Egyesulet lapja = official journal of the Hungarian Association of Psychopharmacology · 2010
Barriers to antiviral treatment in hepatitis C infected intravenous drug users.
СтатьяПоддержка исследования: вне правительства СШАНазвание и аннотация: Перевод в очереди
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…
Ошибки и ограничения
История · было → стало
Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.
Gazdag Gabor, Horvath Gergely, Szabo Olga, Ungvari Gabor S
Аннотация
BACKGROUND: Nowadays intravenous drug use is the main source of hepatitis C transmission, but only a small proportion of those who acquired infection via intravenous drug use receive antiviral treatment.
AIM: to assess the barriers of access to antiviral treatment of infected intravenous drug users.
METHODS: A retrospective chart review was carried out in a hepatology outpatient clinic including all hepatitis C infected intravenous drug users in a 3-year period.
RESULTS: Only one-third of the infected former intravenous drug users received antiviral treatment. The main barrier to antiviral treatment was the lack of abstinence. Former intravenous drug users in prison or in long-term drug rehabilitation institutes were more likely to enter antiviral treatment.
CONCLUSIONS: The low proportion of patients entering antiviral treatment calls the attention to further improving the pretreatment management of this patient population. Special attention should be paid to the maintenance of abstinence.
AIM: to assess the barriers of access to antiviral treatment of infected intravenous drug users.
METHODS: A retrospective chart review was carried out in a hepatology outpatient clinic including all hepatitis C infected intravenous drug users in a 3-year period.
RESULTS: Only one-third of the infected former intravenous drug users received antiviral treatment. The main barrier to antiviral treatment was the lack of abstinence. Former intravenous drug users in prison or in long-term drug rehabilitation institutes were more likely to enter antiviral treatment.
CONCLUSIONS: The low proportion of patients entering antiviral treatment calls the attention to further improving the pretreatment management of this patient population. Special attention should be paid to the maintenance of abstinence.